Health Condition 1: L80- Vitiligo
Conditions
Interventions
Intervention1: Topical Tacrolimus gel/ointment: Patients will be randomized into 2 groups. One will receive Topical Tarcolimus gel/ointment in standard doses of 0.1% twice daily for total duration of
Sponsors
Dr Imran Majid
Dr Sehar Imran
Eligibility
Inclusion criteria
Inclusion criteria: Patients with a confirmed diagnosis of Facial vitiligo for any duration, Body surface area involvement washout period for Systemic therapy for vitiligo before enrolment, Written informed consent signed by the patient or legally acceptable representative(s) in line with applicable regulation of country, Planned treatment in line with the Summary of Product Characteristics
Exclusion criteria
Exclusion criteria: any contraindication to any of the topical medications, women of childbearing age, pregnancy, lactation, hypersensitivity to any of the topical agents, unwillingness to conform to study protocol
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The study is being planned to conduct a comparative repigmenting efficacy of topical Tofacitinib ointment with topical Tacrolimus ointment in facial vitiligo.Timepoint: 1 year | — |
Secondary
| Measure | Time frame |
|---|---|
| To obtain safety information in terms of adverse events on the use topical Tofacitinib versus topical Tacrolimus in facial vitiligo.Timepoint: 1 year | — |
Countries
India
Contacts
Public ContactDr Imran Majid
Cutis Institute of Dermatology
Outcome results
None listed